- Colorado school drops sexual harassment label on boy who kissed girl’s hand
- Australia court strikes down 5-day-old, gay-marriage law
- Fake interpreter at Mandela service: ‘Sorry,’ I have schizophrenia
- George Zimmerman will not be charged in domestic dispute
- Russian officials press bilateral U.S. trade deal
- Creator of ‘Selfies at Funerals’ blog retires after Obama flub: ‘Our work here is done’
- New Obama adviser Podesta is against Keystone but will steer clear of pipeline deliberations
- 40 Australian adults, children found in ‘one of the worst accounts of incest ever made public’
- Venezuela’s Maduro calls on student ‘price vigilantes’ to hit the streets, report businesses
- Atheists smug as Hindus join Satanists to demand display at Oklahoma Statehouse
Indian court to rule on generic drug industry
Question of the Day
NEW DELHI (AP) — From Africa’s crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will determine whether India’s drug companies can continue to provide cheap versions of many life-saving medicines.
The case — involving Swiss drug maker Novartis AG’s cancer drug Glivec — pits aid groups that argue India plays a vital role as the pharmacy to the poor against drug companies that insist they need strong patents to make drug development profitable. A ruling by India’s Supreme Court is expected in early 2013.
“The implications of this case reach far beyond India, and far beyond this particular cancer drug,” said Leena Menghaney, from the aid group Doctors Without Borders. “Across the world, there is a heavy dependence on India to supply affordable versions of expensive patented medicines.”
With no costs for developing new drugs or conducting expensive trials, India’s $26 billion generics industry is able to sell medicine for as little as one-tenth the price of the companies that developed them, making India the second-largest source of medicines distributed by UNICEF in its global programs.
Indian pharmaceutical companies such as Cipla, Cadila Laboratories and Lupin have emerged over the past decade as major sources of generic cancer, malaria, tuberculosis and AIDS drugs for poor countries that can’t afford to pay Western prices.
The 6-year-old case that just wrapped up in the Supreme Court revolves around a legal provision in India’s 2005 patent law that is aimed at preventing companies from getting fresh patents for making only minor changes to existing medicines — a practice known as “evergreening.”
Novartis‘ argued that a new version of Glivec — marketed in the U.S. as Gleevec — was a significant change from the earlier version because it was more easily absorbed by the body.
India’s Patent Controller turned down the application, saying the change was an obvious development, and the new medicine was not sufficiently distinct from the earlier version to warrant a patent extension.
Patient advocacy groups hailed the decision as a blow to “evergreening.”
But Western companies argued that India’s generic manufacturers were cutting the incentive for major drug makers to invest in research and innovation if they were not going to be able to reap the exclusive profits that patents bring.
Earlier this year, an Indian manufacturer was allowed to produce a far cheaper version of the kidney and liver cancer treatment sorefinib, manufactured by Bayer Corp.
Bayer was selling the drug for about $5,600 a month. Natco, the Indian company, said its generic version would cost $175 a month, less than 1/30th as much. Natco was ordered to pay 6 percent in royalties to Bayer.
Novartis says the outcome of the new case will not affect the availability of generic versions of Glivec because it is covered by a grandfather clause in India’s patent law. Only the more easily absorbed drug would be affected, Althoff said, adding that its own generic business, Sandoz, produces cheap versions of its drugs for millions across the globe.
By Matt Kibbe
The short-term deal will assure long-term overspending
- Rand Paul: Budget deal 'shameful,' 'huge mistake'
- All-out war breaks out in GOP over budget pact
- Teen thugs in D.C. run wild -- even while wearing GPS ankle bracelets
- Obama takes 'selfie' at Mandela's funeral service
- Chinese man fed up with his girlfriend's shopping jumps to his death
- Biden guarantees victory on immigration reform
- Inside the Ring: China targets Global Hawk drone
- Obama's antics at Nelson Mandela tribute: Jovial conversation, handshake with Raul Castro
- KIBBE: Another Republican budget surrender
- American bourbon now better than Scottish whisky: U.K.-born expert
Independent voices from the The Washington Times Communities
Al Maurer provides a common sense, conservatarian, Constitutional conservative perspective from the battleground state of Colorado
Interviews and show reviews from the Los Angeles punk scene past and present. Los Angeles has always been rich in punk rock talent since punk rock was born.
Buzz on Bees is a column promoting the love and life of God’s greatest pollinators on earth: The Honeybee
Brazen, leading-edge, “call it like it is” columns and reporting from Ohio native, radio host and writer, Sara Marie Brenner.
Extraordinary day at Redskins Park
White House pets gone wild!
Let it snow